$1.49
2.76% yesterday
Nasdaq, Aug 25, 10:00 pm CET
ISIN
US7291391057
Symbol
PLRX

Pliant Therapeutics Inc Stock price

$1.49
-0.08 5.10% 1M
-1.68 53.00% 6M
-11.68 88.69% YTD
-11.96 88.92% 1Y
-18.86 92.68% 3Y
-22.97 93.91% 5Y
-19.81 93.00% 10Y
-19.81 93.00% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
+0.04 2.76%
ISIN
US7291391057
Symbol
PLRX
Industry

Key metrics

Basic
Market capitalization
$91.5m
Enterprise Value
$-141.0m
Net debt
positive
Cash
$262.9m
Shares outstanding
61.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 40.3
EV/Sales
- | negative
EV/FCF
0.8
P/B
0.4
Financial Health
Equity Ratio
76.6%
Return on Equity
-69.2%
ROCE
-77.4%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $2.3m
EBITDA
$-214.3m | $-148.9m
EBIT
$-216.2m | $-170.3m
Net Income
$-207.0m | $-162.2m
Free Cash Flow
$-170.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-4.2% | 34.2%
EBIT
-4.0% | 25.4%
Net Income
-11.6% | 22.9%
Free Cash Flow
-22.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -6,568.5%
EBIT
-
Net
- | -7,153.7%
Free Cash Flow
-
More
EPS
$-3.4
FCF per Share
$-2.8
Short interest
5.5%
Employees
171
Rev per Employee
$0.0
Show more

Is Pliant Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Pliant Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Pliant Therapeutics Inc forecast:

7x Buy
37%
12x Hold
63%

Analyst Opinions

19 Analysts have issued a Pliant Therapeutics Inc forecast:

Buy
37%
Hold
63%

Financial data from Pliant Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 57 57
5% 5%
-
- Research and Development Expense 159 159
8% 8%
-
-214 -214
4% 4%
-
- Depreciation and Amortization 1.89 1.89
8% 8%
-
EBIT (Operating Income) EBIT -216 -216
4% 4%
-
Net Profit -207 -207
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pliant Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pliant Therapeutics Inc Stock News

Neutral
GlobeNewsWire
19 days ago
BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in integrin-based drug development, today p...
Neutral
GlobeNewsWire
about 2 months ago
Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Compa...
Neutral
GlobeNewsWire
3 months ago
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025.
More Pliant Therapeutics Inc News

Company Profile

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.

Head office United States
CEO Bernard Coulie
Employees 171
Founded 2015
Website pliantrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today